Lung Cancer Survival with Current Therapies and New Targeted Treatments: A Comprehensive Update from the Srinagarind Hospital-Based Cancer Registry from (2013 to 2017)

Abstract

Background: Lung cancer (LC) is a common malignancy and leading cause of cancer death worldwide and in Thailand. An update on LC survival factors after diagnosis at Srinagarind Hospital is needed. Methods: We conducted a retrospective cohort study, and the data were sourced from the Srinagarind Hospital-Based Cancer Registry. All LC cases were diagnosed between January 1, 2013, and December 31, 2017, and followed up until November 30, 2019. Cases of LC (ICD-O-3) numbered 2,149, but only those with coding C34.0-C34.9 were included. The survival rate was estimated using Kaplan-Meier, while the Log-rank test was used to estimate survival. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazard regression models. Results: The 2,149 patients had a total follow-up of 269.6 person-years. Overall, 1,867 patients died during the study, for a corresponding case-fatality mortality rate of 86.0 per 100 person-years. The respective 1-, 3-, and 5-year survival rate was 31.2 % (95% CI; 29.21 to 33.15%), 12.9 % (95%CI: 11.49 to 14.45), and 10.2% (95%CI: 8.74 to 11.70). After patient diagnosis, the median survival time was 0.46 years (5.51 months) (95% CI: 0.42 to 0.50). Targeted therapy was associated with longer survival than non-targeted therapy (p-value < 0.001). After adjusting for sex, TNM stage, and histologic type, multivariable analysis of the entire cohort identified chemotherapy as an independent predictor of improved survival (adjusted HR= 0.48; 95% CI: 0.42 to 0.55; P < 0.001), and that sex, TNM stage, and histologic type were associated with survival. Conclusion: The study confirmed that sex, stage of disease, histology, and chemotherapy are associated with survival of LC. Primary prevention and screening for early detection improve survival. Further investigations into factors affecting survival of LC in Northeast Thailand should focus on targeted therapy.

Calycosin Inhibits the Malignant Behaviors of Lung Adenocarcinoma Cells by Regulating the circ_0001946/miR-21/GPD1L/HIF-1α Signaling Axis

“…The prevalence of LUAD is increasing annually and is about to become the main subtype of NSCLC [ 2 ]. Despite improvements in early diagnosis, patients with LUAD still have a low 5-year overall survival rate and unsatisfactory recurrence rate [ 3 , 4 ]. Currently, the clinical treatment protocols for LUAD mainly include drugs and radiotherapy; however, they are often prone to tolerance in patients [ 5 ].…”

A Microarray Study on the Expression of ANKRD49 in Lung Squamous Cell Carcinoma and Its Clinicopathologic Significance

“…13 Emerging evidences have demonstrated that hyperactivation of oncogenes and/or low expression of tumor suppressor genes obviously promotes the occurrence and development of LUSC. 2,4,14 In view of the fact that LUSC lacks targeted agents available compared with lung adenocarcinoma, 3,15 identification of biomarkers that are involved in the occurrence and development of cancer cells may provide helpful candidates for clinical outcome prediction and clinical targeted therapy.…”

Survival of Lung Cancer Patients by Histopathology in Taiwan from 2010 to 2016: A Nationwide Study

“…Two decades later, there are 71 small molecular kinase inhibitors approved by the U.S. FDA [ 23 ]. For advanced NSCLCs harboring activating EGFR mutations, an EGFR-TKI provides a superior survival benefit compared with platinum-based chemotherapy [ 24 , 25 ]. Osimertinib, another potent EGFR-TKI, was shown to be highly active in patients who had resistance to previous EGFR inhibitors [ 26 ].…”